Patents by Inventor Naohiko KOSHIKAWA

Naohiko KOSHIKAWA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LAMC2-NR6A1 Splicing Variant and Translation Product Thereof
    Publication number: 20230340580
    Abstract: The present invention relates to a splicing variant derived from exon 12 of laminin ?2 (LAMC2) gene and intron 1 of the antisense strand of NR6A1 gene.
    Type: Application
    Filed: February 24, 2021
    Publication date: October 26, 2023
    Inventors: Naohiko Koshikawa, Motoharu Seiki, Daisuke Hoshino
  • Cancer examination method and examination kit
    Patent number: 11422126
    Abstract: An object of the present invention is to elucidate a molecular mechanism of ligand-independent activation of EphA2 in cancer cells, make EphA2 a more useful target in the treatment of cancer, and provide a cancer testing method and the like using the mechanism. The present invention provides, for example, a cancer testing method including a step of measuring an amount of an EphA2 protein fragment having a molecular weight of from 30 kDa to 80 kDa in a sample derived from a subject.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 23, 2022
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Motoharu Seiki, Naohiko Koshikawa
  • Methods of diagnosing hepatocellular carcinoma and pancreatic cancer
    Patent number: 11340229
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 24, 2022
    Assignees: Abbott Japan LLC, The University of Tokyo
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • METHODS OF DIAGNOSING HEPATOCELLULAR CARCINOMA AND PANCREATIC CANCER
    Publication number: 20190242899
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 8, 2019
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • CANCER EXAMINATION METHOD AND EXAMINATION KIT
    Publication number: 20190064149
    Abstract: An object of the present invention is to elucidate a molecular mechanism of ligand-independent activation of EphA2 in cancer cells, make EphA2 a more useful target in the treatment of cancer, and provide a cancer testing method and the like using the mechanism. The present invention provides, for example, a cancer testing method including a step of measuring an amount of an EphA2 protein fragment having a molecular weight of from 30 kDa to 80 kDa in a sample derived from a subject.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 28, 2019
    Inventors: MOTOHARU SEIKI, NAOHIKO KOSHIKAWA
  • METHODS OF DIAGNOSING HEPATOCELLULAR CARCINOMA AND PANCREATIC CANCER
    Publication number: 20170089905
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 30, 2017
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • CANCER EXAMINATION METHOD AND EXAMINATION KIT
    Publication number: 20160103121
    Abstract: An object of the present invention is to elucidate a molecular mechanism of ligand-independent activation of EphA2 in cancer cells, make EphA2 a more useful target in the treatment of cancer, and provide a cancer testing method and the like using the mechanism. The present invention provides, for example, a cancer testing method including a step of measuring an amount of an EphA2 protein fragment having a molecular weight of from 30 kDa to 80 kDa in a sample derived from a subject.
    Type: Application
    Filed: February 13, 2014
    Publication date: April 14, 2016
    Inventors: Motoharu SEIKI, Naohiko KOSHIKAWA